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Abstract
Several viruses have the capacity to cause serious infections of the nervous system in patients who are immunosuppressed. 
Individuals may be immunosuppressed because of primary inherited immunodeficiency, secondary immunodeficiency due to 
particular diseases such as malignancy, administration of immunosuppressant drugs or organ or bone marrow transplantation. 
The viruses capable of such opportunistic infection of the nervous system include herpes simplex virus (HSV), Varicella-
Zoster virus (VZV), Cytomegalovirus (CMV), Epstein –Barr virus (EBV), Human Herpes virus type 6 (HHV-6), JC virus 
(JCV), enterovirus, measles virus and Covid-19. In most cases it seems likely that immunological defence mechanisms in 
the immunosuppressed are deficient which creates a suitable environment for certain viruses to become opportunistic in the 
nervous and other systems. Further research is required both to understand these opportunistic mechanisms in more detail 
and also to determine how many virus infections are modified by specific inborn errors of immunological responses.
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Introduction
An individual may become immunocompromised as a 
result of multiple factors. These include the administra-
tion of immunosuppressant drugs given for various medical 
conditions, an underlying disease such as Human Immu-
nodeficiency Virus (HIV) infection or malignancy such 
as lymphoma which affects the immune system producing 
secondary immunodeficiency, various primary immunode-
ficiency syndromes such as severe combined immunode-
ficiency (SCID) with defects in T cells, B cells, and NK 
cells [1], or from organ or bone marrow transplantation. In 
practice, these factors are often present in the same patient 
so they do not act in isolation as in the case of a patient 
who receives immunosuppressant drugs to suppress organ 
rejection after bone marrow or organ transplantation. Immu-
nosuppressant drugs include corticosteroids, chemotherapy 
for malignant diseases or for autoimmune and inflammatory 
conditions, targeted monoclonal antibody therapy, and drugs 
given as anti-rejection therapy [2, 3].
Viruses may reactivate under conditions of immunosup-
pression from various causes primarily because the immune 
mechanisms that normal suppress or limit viral replication 
become disrupted. In the situation of latent virus infection 
which is kept in check by the immune system the virus may 
reactivate and cause neurological disease. For example, 
in the case of Varicella Zoster (VZV) infection, following 
primary infection (chicken pox) the virus becomes latent 
in neurons in peripheral ganglia [4]. It may then reactivate 
causing herpes zoster (shingles), more commonly in condi-
tions of immunosuppression, for instance in the elderly who 
have impaired cell mediated immunity (CMI) to VZV [5, 6]. 
Other conditions or drugs impairing CMI also increase the 
risk of VZV reactivation with possible neurological com-
plications. A virus may more commonly infect individuals 
with waning or impaired immunity or it may cause a more 
severe infection, or it may do both.
Here I give an overview of the several viruses which have 
a propensity to replicate and/or reactivate under conditions 
of immunosuppression causing neurological disease. These 
include Herpes viruses including Herpes Simplex Virus type 
1 and 2 (HSV-1, HSV-2), VZV, Cytomegalovirus (CMV), 
Epstein Barr virus (EBV) and Human Herpes Virus type 
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6 (HHV-6). Also included here is JC Virus, and, in brief, 
enteroviruses, measles and the recently recognised Covid-19 
(SARS-CoV2) infection. In many cases there is included an 
indication of the Class of Evidence and Level of Recom-
mendation for a therapeutic intervention or an investigative 
procedure, and these are based on previously published cri-
teria which are also used for official European Academy of 
Neurology guidelines [7, 8, 9].
Specific viral infections 
in the immunosuppressed
Herpes simplex virus (HSV)
While HSV-1 is classically associated with herpes simplex 
encephalitis (HSE) [10], HSV-2 accounts for about 10% of 
cases of HSE and when it does so it is typically associated 
with immunosuppression [11] so is of greater relevance to 
the current overview. The typical clinical features of HSE 
are well recognised with predominant involvement of the 
fronto-temporal brain regions. It should also be mentioned 
that immunodeficiencies involving the Toll-like receptor 3 
(TLR3) pathway are well established, at least in children, to 
predispose to HSE [12]. Children with this immune defect 
are also likely to have relapses of HSE [13]. Treatment of 
HSE due to both viruses is well established to be with intra-
venous acyclovir 30 mg/Kg/day for 10–14 days given as 
10 mg/kg given as an intravenous infusion over one hour 
three times daily (Class 1), though in the immunosuppressed 
patient the duration of therapy should be 21 days [8] (Class 
IV). Further, after reactivation from lumbosacral ganglia 
where the virus may remain in a latent form for many years, 
HSV-2 can cause genital herpes and has been reported as a 
likely cause of lumbosacral radiculopathy [14] particularly 
in the immunosuppressed state. A diagnosis in both condi-
tions can be achieved using cerebrospinal fluid (CSF) Poly-
merase Chain Reaction (PCR) to detect HSV-2 DNA (Class 
1, Level A) [9] Treatment should again be with acyclovir. 
Mild or atypical HSVE may be associated with infection 
with either HSV-1 or HSV-2. Thus, a retrospective study 
using PCR analysis found that mild or atypical HSV enceph-
alitis, due to either HSV-1 or HSV-2, was frequently associ-
ated with an immunocompromised state and they reported 
that an asymmetric HSV infection affecting predominantly 
the non-dominant temporal lobe was typical [15].
Varicella‑Zoster virus (VZV)
Reactivation of latent VZV from human ganglia is a well-
recognised complication of immunsuppression resulting 
in a variety of neurological complications, due, as indi-
cated above, to symptomatic impairment of cell-mediated 
immunity to the virus. Indeed VZV infections are among the 
most important of all viral infections that affect the central 
nervous system (CNS) and peripheral nervous system (PNS) 
in immunocompromised individuals. The protean manifes-
tations of VZV-induced neurological disease have been 
described in detail elsewhere [6], but the main complications 
include herpes zoster (shingles) followed by post-herpetic 
neuralgia (PHN) in some cases the incidence of which rises 
with increasing age, VZV vasculopathy, myelitis, and zoster 
sine herpete where VZV reactivates in the absence of the 
typical zosteriform rash [16, 17, 18]. In chronic graft versus 
host disease following bone marrow transplantation VZV 
reactivation is also a recognised opportunistic viral infec-
tion that may mimic lymphoma [19]. Treatment should be 
given to immunocompromised patients with herpes zoster 
consisting of intravenous acyclovir (in adults 10–15 mg/
Kg 8 hrly for 10–14 days and in children 500 mg/m2 for 
7–10 days) (Class IV). The role of acylcovir in imunocom-
petent individuals below 50 years is less clear. In patients 
with VZV-induced myelitis and vasculopathy it has been 
suggested that treatment should be with intravenous acy-
clovir for 14 days in combination with oral prednisolone 
for 5–7 days but this is based on experience with only a 
small number of patients [20] (Class IV). The diagnosis of 
an opportunistic VZV infection, including zoster sine her-
pete can be obtained using PCR to detect VZV DNA in the 
CSF (Class III, Level C), though detection of anti-VZV IgG 
in the CSF has a higher sensitivity for correctly diagnos-
ing VZV vasculitis than does PCR [21]. The importance 
of host immunogenetics in determining VZV infection of 
the nervous system has recently been demonstrated. Thus it 
was shown that defects in the DNA sensor RNA polymer-
ase III (POL III) confer selective increased susceptibility 
to infection of the central nervous system (CNS) causing 
encephalitis [22, 23] and such hereditary immune defects 
may result in reduced production of Type 1 Interferon which 
reduces the host’s anti-viral capacity. The role of zoster vac-
cination for the immunocompromised patient is currently 
not established.
Cytomegalovirus (CMV)
CMV infection has an increased incidence under condi-
tions of immunosuppression, particularly in patients with 
HIV infection. The virus can affect both the CNS and the 
PNS. Encephalitis and ventriculitis are recognised as well 
as retinitis. In the PNS an acute lumbosacral polyradicu-
lopathy is well recognised, may be painful, and is associated 
with a CSF pleocytosis in half the cases and the MRI shows 
enhancing lesions in the conus, cauda equina and lumbosa-
cral nerve roots [14]. Also recognised are mononeuritis 
multiplex, and myeloradiculopathy, and all these conditions 
can be confirmed using CSF PCR for CMV DNA with over 
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90% sensitivity and specificity [9] (Class II, Level B). CMV 
reactivation is particularly associated with renal transplan-
tation. Though Guillain–Barre syndrome (GBS) and CMV 
polyradiculopathy are known to be associated with CMV 
infection, these conditions occur primarily in immunocom-
petent individuals. Where GBS occurs established treatment 
is with intravenous immunoglobulin (Class 1, Level A). 
Antiviral therapy of CNS and PNS CMV infections is not 
very satisfactory with data from controlled antiviral trials in 
CMV-induced neurological disease lacking. Gangciclovir, 
foscarnet and cidofovir have all been used, with combina-
tion therapy (gangciclovir and foscarnet) reported as being 
more effective than monotherapy in the important induction 
phase of CMV encephalitis [8] (Class 4). Such treatment 
can be followed by monotherapy with either of these two 
drugs, with a total duration of 6 weeks treatment in immu-
nosuppressed individuals. In the PNS conditions one option 
is to give intravenous gangciclovir as first line therapy for 
14–21 days.
Epstein‑Barr virus (EBV)
EBV infection of the nervous system can occur in both 
immunocompetent and immunosuppressed individuals, with 
the latter at greater risk of this infection especially if they 
also have HIV infection giving an increased risk of primary 
CNS lymphoma [24]. Most of our information is based on 
case reports and serological data in immunocompetent indi-
viduals as such infections are relatively uncommon (so only 
Class IV evidence). The neurological conditions known to 
be associated with EBV include plexopathy or radiculoplex-
opthy, acute radiculits, acute autonomic neuropathy and cra-
nial neuropathies [14]. A rare complication of solid organ 
transplantation is a primary CNS post-transplant lymphopro-
liferative disorder and is typically an EBV-induced lym-
phoma, the risk being dependent on the type of transplant 
and the degree of immunosuppression [25]. CSF PCR for 
EBV DNA has a high sensitivity and specificity between 97 
and 100% [9] (Class IV, Level C). No antiviral agents have 
been shown to be effective so far against EBV infections.
Human herpes virus type 6 (HHV‑6)
HHV-6 is a human herpes virus that is capable of reacti-
vation in patients who are immunosuppressed including 
transplant patients. Following bone marrow transplanta-
tion HHV-6 may rarely cause encephalitis, typically being 
an opportunistic infection occurring in the period between 
pancytopaenia and chronic graft versus host disease [19]. 
HHV-6 has also been implicated in encephalitis or menin-
goencephalitis in immunocompromised persons, including 
HIV-positive individuals [26]. Anti-viral therapy that has 
been used in HHV-6 encephalitis includes foscarnet (for 
both HHV-6A and HHV-6B variants) and gangciclovir as 
an alternative for encephalitis caused by the HHV-6 B vari-
ant [8].
JC virus (JCV)
JCV-induced progressive multifocal encephalopathy (PML) 
is a demyelinating disease associated mainly with immu-
nosuppression, especially AIDS (5% at post-mortem), 
organ transplants, leukaemia, and the Multiple Sclerosis 
drug Natalizumab (Tysabri) [27, 28, 29]. It is caused by 
the polyoma virus JCV infecting oligodendrocytes causing 
demyelination and multifocal neurological features such as 
motor, cognitive, visual deficits, ataxia, and seizures with 
a progressive course. The CSF is typically non-inflamma-
tory and normal, JCV antibody detection is useful and CSF 
PCR for JCV DNA is now an established method of diag-
nosis though a definitive diagnosis of PML can be made by 
brain biopsy. MRI imaging shows varied features includ-
ing confluent multifocal white matter hyperintensities on 
T2-weighted images, usually without enhancement on post-
contrast T1 weighted images. Contrast enhancement is seen 
in the context of Natalizumab and other situations where 
there is an immune reconstitution inflammatory syndrome. 
The prognosis is very poor, and there is no clearly effective 
treatment. While the specificity of JCV PCR is very good at 
around 98.5–100%, the sensitivity is variable and much less 
reliable at around 50–82% (Class II, Level B).
Other viruses that may be more serious 
in the immunosuppressed
Enterovirus
While enteroviruses such as poliovirus, echoviruses and 
coxsackie viruses are known to infect the immunocom-
petent human host causing a range of diseases including 
those of the CNS such as encephalitis, they may also be 
significant in the immunocomprised individual. Diseases 
such as meningitis, myocarditis and myopathy can be more 
common in the immunocompromised or neonatal host [30]. 
Of particular relevance here is the occurrence of a chronic 
meningoencephalitis in immunocompromised patients, and 
in particular those suffering from X-linked agammaglobu-
linemia in whom this chronic CNS infection is the common-
est cause of death [30]. The diagnosis may be established by 
Reverse transcription (RT)‐PCR in the CSF for enterovirus. 
While the CSF specificity of this assay appears to be high 
(92–100%), the sensitivity is less certain with reports vary-
ing between about 31–95% (Class II, Level B) [9].
 Journal of Neurology
1 3
Measles virus
While measles virus infection, normally a fairly mild though 
certainly uncomfortable condition, has the capacity to be 
serious in the immunocompetent, it is typically a far more 
dangerous infection in the immunosuppressed. Measles may 
rarely be followed by an acute post-measles encephalitis, 
which is the most common CNS complication in the immu-
nocompetent as well as a rare primary measles encephalitis. 
Immunodeficient children are susceptible to measles inclu-
sion body encephalitis where the measles virus persists in 
the brain. The latter is a very serious infection with a mortal-
ity of 75% [31]. In a report of four children with presumed 
measles inclusion body encephalitis who were treated for 
lymphatic malignancies by immunosuppressive drugs it was 
found that epilepsia partialis continua was a prominent fea-
ture in three patients, and all cases were fatal [32]. In these 
latter children measles virus was isolated from the brain in 
one case and identified immunologically in another, and 
measles virus nucleocapsids identical to those seen in suba-
cute sclerosing panencephalitis (SSPE), a rare and invari-
ably fatal complication of measles virus infection, were also 
identified in three of these patients. Two of the patients had 
impaired cellular immunity [32] which presumably favours 
the persistence of measles virus in the brain. Clearly, mea-
sles virus is a very significant opportunistic infection in pat-
ents who are immunsuppressed.
Covid‑19
In the author’s view, it is relevant to mention this recently 
recognised infection in the current context. It is known that 
malignant disease predisposes to Covid-19 infection with 
7.2% of 138 patients having malignant disease as a co-
morbidity in 1 major study [33]. Neurological features are 
now well recognised in Covid-19 infection indicating that 
the virus is neurotropic and include encephalitis, meningi-
tis, myalgia and myositis, acute cerebrovascular disease, 
anosmia, Guillain–Barre syndrome, post-infectious acute 
disseminated myelitis and brainstem encephalitis [34, 35]. 
Since the infection is typically more serious in the elderly in 
whom the immune system is weaker, in terms of decreased 
cell-mediated immunity compared with younger individuals, 
in this sense at least a compromised immune system could 
predispose to neurological features. Further, not only does 
lymphopaenia occur as the Covid-19 infection progresses 
[36], but a pre-existing lymphopaenia secondary to cancer 
chemotherapy itself predisposes to Covid-19 infection (37). 
Since neurological complications are usually part of a more 
severe type of disease it seems likely that immunosuppres-
sion of some kind likely increases the chances of such com-
plications occurring. It remains to be seen whether there are 
specific inborn errors of immunity that might predispose to 
particular neurological features in this infection.
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